Tag Archives: Kevin Degeeter
Oppenheimer Issues a Buy Rating on BioNano Genomics (BNGO)
Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to BioNano Genomics (BNGO – Research Report) today and set a price target of $15.00. The company’s shares closed last Tuesday at $8.37. According to TipRanks.com, DeGeeter is a top 100 analyst
Analysts Offer Insights on Healthcare Companies: DermTech (NASDAQ: DMTK) and Kadmon Holdings (NASDAQ: KDMN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DermTech (DMTK – Research Report) and Kadmon Holdings (KDMN – Research Report) with bullish sentiments. DermTech (DMTK) Oppenheimer analyst Kevin DeGeeter maintained
Personalis (PSNL) Receives a Rating Update from a Top Analyst
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Hold rating on Personalis (PSNL – Research Report). The company’s shares closed last Monday at $37.93. According to TipRanks.com, DeGeeter is a top 100 analyst with an average return
What Made Oppenheimer Downgrade Personalis’ Stock?
Personalis (PSNL – Research Report) received a Hold rating from Oppenheimer analyst Kevin DeGeeter today. The company’s shares closed last Thursday at $26.77, close to its 52-week high of $30.95. According to TipRanks.com, DeGeeter is a 5-star analyst with an
Fulgent Genetics (FLGT) Receives a Buy from Oppenheimer
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Fulgent Genetics (FLGT – Research Report) today and set a price target of $75.00. The company’s shares closed last Friday at $32.53. According to TipRanks.com, DeGeeter is a 5-star analyst with
Oppenheimer Believes Spero Therapeutics (NASDAQ: SPRO) Won’t Stop Here
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Spero Therapeutics (SPRO – Research Report) today and set a price target of $19.00. The company’s shares closed last Friday at $14.02, close to its 52-week high of $14.60. According to
